Moxonidine-SZ, 0.2 mg 28 pcs.

Hypertension (high blood pressure)

Arterial hypertension.

Active ingredient

Composition

1 film-coated tablet contains: dosage 0.2 mg:

the active ingredient:

moxonidine 0.2 mg

excipients (core):

croscarmellose sodium (primellose) – 3.0 mg;

lactose monohydrate (lactopress) (milk sugar) -; 95.3 mg;

Colloidal silica (aerosil) -; 0.5 mg;

sodium stearyl fumarate -; 1.0 mg;

accompanied substances (coating):

Opadray II (polyvinyl alcohol, partially hydrolyzed -; 1.32 mg;

titanium dioxide E 171 -; 0.6027 mg;

talc -; 0.6 mg;

macrogol (polyethylene glycol 3350) -; 0.3705 mg;

soybean lecithin E 322 -; 0.105 mg;

iron oxide (II) yellow dye -; 0.0003 mg;

iron oxide (II) red dye -; 0.0015 mg).

How to take, the dosage

Ingestion, regardless of meals, with plenty of fluid. In most cases, the initial dose of moxonidine is 0.2 mg per day, in a single dose, preferably in the morning hours. If the therapeutic effect is insufficient, the dose may be increased after 3 weeks of therapy to 0.4 mg per day in 2 doses or a single dose.

The maximum daily dose to be divided into 2 doses (morning and evening) is 0.6 mg. The maximum single dose is 0.4 mg.

In elderly patients with normal renal function, the dosage recommendations are the same as in adult patients.

In patients with renal insufficiency (cretinine clearance 30-60 ml per minute) and patients on hemodialysis, the single dose should not exceed 0.2 mg; the maximum daily dose is 0.4 mg.

Interaction

Moxonidine may be prescribed with thiazide diuretics and “slow” calcium channel blockers. When co-administration of moxonidine with these and other hypotensive agents there is a mutual enhancement of moxonidine action.

When prescribing moxonidine with hydrochlorothiazide, glibenclamide (gliburide) or digoxin there is no pharmacokinetic interaction.

Tricyclic antidepressants may decrease the effectiveness of centrally acting antihypertensive agents.

Beta-adrenoblockers increase bradycardia, the severity of the negative ino- and dromotropic effects of moxonidine.

Moxynidine moderately enhances impaired cognitive ability in patients taking lorazepam.

The administration of moxonidine together with benzodiazepines may be accompanied by an increased sedative effect of the latter.
There is no pharmacodynamic interaction when prescribing moxonidine together with moclobemide.

Special Instructions

Contraindications

Side effects

Overdose

There have been reports of several non-fatal overdoses when doses up to 19.6 mg were used at one time.

Symptoms: headache, sedation, marked BP decrease, dizziness, asthenia, bradycardia, dry mouth, vomiting, increased fatigue, epigastric pain, respiratory depression and impaired consciousness. In addition, transient BP elevation, tachycardia, and hyperglycemia are also possible, as has been shown in several high-dose animal studies.

Treatment

There is no specific antidote. In cases of marked BP decrease, restoration of circulating blood volume may be required by administration of fluids and dopamine (by injection). Bradycardia may be stopped by atropine (injection). In severe cases of overdose, it is recommended to carefully control impaired consciousness and avoid respiratory depression. Alpha-adrenoceptor antagonists may reduce or eliminate the paradoxical hypertensive effects of moxonidine overdose. Moxonidine is slightly excreted by hemodialysis.

Similarities